CD38 and systemic lupus erythematosus: Lastly, using whole-genome microarray analysis, a significant elevation of the plasma cell signature was also identified in more than 30% of blood and skin specimens from SLE patients, suggesting that these methods may be useful in order to select patients with the highest likelihood of response to therapies targeted against plasma cells, including anti-CD38 antibodies [33].